Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.

The treatments for multiple myeloma in the NHS have changed since this guidance was first published. So we have updated the recommendations in section 1 of the guidance and explained this change in sections 4.25 and 4.26. No other sections of the guidance have been updated, so these are the same as in the original guidance.

 table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions on using carfilzomib. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.

This guidance has been partially updated by NICE technology appraisal guidance on carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma.

Is this guidance up to date?

Next review: 2023

Commercial arrangement

There is a simple discount patient access scheme for carfilzomib. Contact commercial-team@amgen.com for details.

Guidance development process

How we develop NICE technology appraisal guidance

This guidance updates and replaces NICE technology appraisal guidance on carfilzomib for previously treated multiple myeloma (TA457).

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)